Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
atopic dermatitis
Biotech
Vyne to reevaluate pipeline after eczema fail uproots plans
Vyne’s lead asset has failed to improve the severity of atopic dermatitis, uprooting the biotech’s plans and sending the stock plummeting.
Gabrielle Masson
Aug 10, 2022 11:23am
Amgen hits pause on $400M eczema bet to tweak phase 3 study
Aug 4, 2022 7:00am
Evelo Biosciences pauses dermatitis drug after trail failure
Apr 14, 2022 11:45am
Lilly’s $1B bet yields 'compelling' data on Dupixent rival
Mar 28, 2022 7:40am
J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset
Feb 2, 2022 5:42pm
Novartis JAKs in rival to Incyte after seeing clinical data
Feb 2, 2022 7:30am